Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease

International Journal of Radiation Oncology Biology Physics

Volumn 81, Issue 4, 2011, Pages

  Stenmark, Matthew H ^a   Blas, Kevin ^a   Halverson, Schuyler ^a   Sandler, Howard M ^b   Feng, Felix Y ^a,c   Hamstra, Daniel A ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

Androgen deprivation therapy; Cause specific survival; Metastasis; Prostate; Salvage therapy

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; CAUSE-SPECIFIC SURVIVAL; METASTASIS; PROSTATE; SALVAGE THERAPY;

DISEASE CONTROL; DISEASES; PATHOLOGY; PATIENT MONITORING;

RADIOTHERAPY;

ANTIANDROGEN; GONADORELIN DERIVATIVE;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RECURRENT CANCER; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RISK; SALVAGE THERAPY;

EID: 80255123770     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.04.037     Document Type: Article

References (34)

1. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974 (Pubitemid 28445094)
2. A.W. Partin, M.W. Kattan, and E.N. Subong Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update JAMA 277 1997 1445 1451 (Pubitemid 27208886)
3. M. Kattan, M. Zelefsky, and P. Kupelian Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer J Clin Oncol 18 2000 3352 3359
4. J. Mohler, R.R. Bahnson, and B. Boston NCCN clinical practice guidelines in oncology: Prostate cancer J Natl Compr Canc Netw 8 2010 162 200
5. S.J. Freedland, E.B. Humphreys, and L.A. Mangold Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy JAMA 294 2005 433 439 (Pubitemid 41124175)
6. M.V. Pilepich, K. Winter, and C.A. Lawton Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: Long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290 (Pubitemid 40470408)
7. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial Lancet 360 2002 103 106
8. M.V. Pilepich, K. Winter, and M.J. John Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252 (Pubitemid 32727802)
9. E.M. Horwitz, K. Bae, and G.E. Hanks Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 2008 2497 2504
10. M. Bolla, T.M. de Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
11. A.L. Zietman, M.L. DeSilvio, and J.D. Slater Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial JAMA 294 2005 1233 1239 (Pubitemid 41352111)
12. D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74 (Pubitemid 350251041)
13. S.T.H. Peeters, W.D. Heemsbergen, and P.C.M. Koper Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy J Clin Oncol 24 2006 1990 1996 (Pubitemid 46622106)
14. D.P. Dearnaley, M.R. Sydes, and J.D. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial Lancet Oncol 8 2007 475 487 (Pubitemid 46805903)
15. M. Gleave, and W.K. Kelly High-risk localized prostate cancer: A case for early chemotherapy J Clin Oncol 23 2005 8186 8191 (Pubitemid 46211553)
16. A. Nanda, M.H. Chen, and A.A. Renshaw Gleason Pattern 5 prostate cancer: Further stratification of patients with high-risk disease and implications for future randomized trials Int J Radiat Oncol Biol Phys 74 2009 1419 1423
17. P.L. Nguyen, M.H. Chen, and W.J. Catalona Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors Int J Radiat Oncol Biol Phys 73 2009 659 664
18. M.W. Kattan, M.J. Zelefsky, and P.A. Kupelian Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer J Clin Oncol 18 2000 3352 3359
19. Z. Symon, K.A. Griffith, and P.W. McLaughlin Dose escalation for localized prostate cancer: Substantial benefit observed with 3D conformal therapy Int J Radiat Oncol Biol Phys 57 2003 384 390 (Pubitemid 37040934)
20. M. Roach 3rd, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
21. O. Yossepowitch, S.E. Eggener, and A.M. Serio Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy Eur Urol 53 2008 950 959 (Pubitemid 351434496)
22. M.J. Zelefsky, S.A. Leibel, and P.B. Gaudin Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer Int J Radiat Oncol Biol Phys 41 1998 491 500 (Pubitemid 28275076)
23. M.J. Zelefsky, Y. Yamada, and Z. Fuks Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes Int J Radiat Oncol Biol Phys 71 2008 1028 1033
24. D.A. Hamstra, K. Bae, and M.V. Pilepich Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: Meta-analysis of Radiation Therapy Oncology Group trials Int J Radiat Oncol Biol Phys 2011 In press
25. G. Arcangeli, L. Strigari, and S. Arcangeli Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer Int J Radiat Oncol Biol Phys 75 2009 975 982
26. M.J. Zelefsky, J.A. Eastham, and A.M. Cronin Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: A comparison of clinical cohorts adjusted for case mix J Clin Oncol 28 2010 1508 1513
27. M. Spahn, C. Weiss, and P. Bader Long-term outcome of patients with high-risk prostate cancer following radical prostatectomy and stage-dependent adjuvant androgen deprivation Urol Int 84 2010 164 173
28. M. Spahn, S. Joniau, and P. Gontero Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: A European multi-institutional study of 712 patients Eur Urol 58 2010 1 7 discussion 10-11
29. A. Widmark, O. Klepp, and A. Solberg Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised phase III trial Lancet 373 2009 301 308
30. I.M. Thompson, C.M. Tangen, and J. Paradelo Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term followup of a randomized clinical trial J Urol 181 2009 956 962
31. T. Wiegel, D. Bottke, and U. Steiner Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95 J Clin Oncol 27 2009 2924 2930
32. M. Bolla, H. Van Poppel, and L. Collette Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911) Lancet 366 2005 572 578 (Pubitemid 41140332)
33. M.K. Buyyounouski, A.L. Hanlon, and E.M. Horwitz Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy Int J Radiat Oncol Biol Phys 70 2008 59 66 (Pubitemid 350251025)
34. A.K. Lee, L.B. Levy, and R. Cheung Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy Int J Radiat Oncol Biol Phys 63 2005 456 462 (Pubitemid 41317162)